

Human-Relevant Non-Animal Methodologies (NAMs)
Specialised Models Series: Cross-Cutting & Safety Platforms
Section 8 – Reference 8.1 - 8.7

Full Scope Roadmap

8.1 Toxicology Models

8.2 Developmental & Reproductive Toxicology (DART)

8.3 Carcinogenicity & Genotoxicity Models

8.4 Aging & Cellular Senescence Models

8.5 Rare Disease Models (cross-cutting)

8.6 Paediatric Disease Models

8.7 3Rs Implementation & Project Licence Support Toolkit

Version 1.0 | June 2026 Edition

Compiled for the Alliance for Cruelty-Free Science by Georgina Rednall

*Prepared for Academic Leadership, Animal Welfare & Ethical Review Bodies (AWERB), and
Principal Investigators*

1. Executive Summary & Legal-Scientific Imperative

Section 2A of the Animals (Scientific Procedures) Act 1986 (ASPA) imposes a statutory duty on the Secretary of State to ensure compliance with the principles of **replacement, reduction and refinement** (the 3Rs). Whenever a scientifically satisfactory method or testing strategy not entailing the use of protected animals is available, it must be used to replace a regulated procedure.

Historically, safety assessment, regulatory toxicology and cross-cutting disease modelling have relied on high-severity, repeat-dose animal testing and long-term rodent bioassays that frequently fail to capture human-specific adverse outcome pathways. Key sources of translational failure include:

- **Xenobiotic metabolic disparities** — significant variations in cytochrome P450 enzyme expression and metabolic clearance rates between laboratory species and humans lead to poor predictive efficacy for drug-induced organ toxicity.
- **Gestation and developmental mismatches** — rodent models fail to mirror human maternal–fetal transport kinetics, endocrine regulation and long-term multi-generational responses required for accurate DART evaluations.
- **Mechanistic carcinogenic divergence** — traditional two-year rodent carcinogenicity assays exhibit low human-predictive sensitivity and high false-positive rates due to species-specific cellular transformation mechanisms that do not reflect human biology.

Accelerating the transition to human-relevant Non-Animal Methodologies (NAMs) is therefore both a scientific necessity to close the translation gap and a statutory mandate for UK academic research programmes under ASPA 1986.

This roadmap sets out a practical transition strategy that leverages multi-organ microphysiological systems (MPS), advanced genotoxicity arrays, patient-specific platforms and a dedicated 3Rs Project Licence Support Toolkit to support institutional Project Licence (PPL) applications.

2. System-Specific NAM Frameworks & Focus Areas

Focus Area	Primary Animal Model	NAM Replacement Technology	Key Benefit under ASPA 1986
8.1 Toxicology	Repeat-dose rodent testing	Multi-Organ Barrier MPS	Tracks long-term drug-induced injury and systemic clearance in human-relevant context
8.2 DART	In-vivo gestational rodent tests	Placental-Chip / hESC differentiation assays	Evaluates maternal–fetal transfer and teratogenic risk without invasive gestational studies
8.3 Carcinogenicity & Genotoxicity	Two-year rodent bioassays	3D human micro-tissue micronucleus assays; in-vitro cell-transformation frameworks	Maps human-specific DNA repair and mutagenic potential; reduces false positives
8.4 Aging & Cellular Senescence	Aged mouse colonies	Induced senescent 3D tissue scaffolds	Monitors SASP secretion without long-term animal housing costs
8.5 Rare Disease (cross-cutting)	Transgenic animal models	Patient-specific iPSC-derived organoids	Isolates precise genetic mutations where animal models are non-existent or divergent
8.6 Paediatric Disease	Juvenile animal testing	Maturing juvenile tissue organoids	Mimics infant/child physiological and metabolic maturation profiles
8.7 3Rs & PPL Support Toolkit	Manual 3Rs review protocols	3Rs Evidentiary Data Bundle Framework	Supplies pre-validated human-relevant data and mechanistic justifications for PPL submission

Table 1. Core specialised platforms and primary replacement rationale under ASPA 1986.

3. Maturity Matrix & Phased Implementation

Institutions should progress through four maturity phases. The pace can be accelerated by prioritising commercially available multi-organ MPS, high-throughput genotoxicity arrays and the 3Rs evidentiary toolkit.

Phase	Focus	Key Activities
Phase 1 – Exploratory	Audit	Audit institutional reliance on traditional regulatory animal toxicity, DART and carcinogenicity models; map high-severity endpoints to available NAMs
Phase 2 – Pilot	Integration	Integrate human-derived multi-organ barrier chips and high-throughput genotoxicity screening platforms; run parallel validation where required
Phase 3 – Integration	Quantitative frameworks	Implement AI-driven adverse outcome pathways (AOP) and computational PBPK software frameworks; generate early WoE packages
Phase 4 – Standardisation	Full replacement	Replace high-severity regulatory safety testing and multi-disease animal modelling with qualified, human-specific NAM arrays; embed 3Rs toolkit in all PPL submissions

Table 2. Four-phase maturity matrix for institutional transition.

Executive Summary & Compliance Dashboard

Executive Summary

Safety testing and regulatory toxicology have historically depended on high-severity animal challenge protocols that do not reflect human-specific toxicodynamics or disease progression across distinct lifespans. This roadmap mandates a transition to high-fidelity, human-relevant NAMs—specifically multi-organ microphysiological systems (MPS), advanced genotoxicity arrays, and patient-specific rare/paediatric disease platforms—to replace legacy animal-based paradigms. This strategic shift ensures all safety assessment and project license generation are scientifically precise, ethically robust, and fully compliant with the Section 2A statutory duty of the *ASPA 1986*.

Maturity Matrix

Phase 1 (Exploratory): Audit institutional reliance on traditional regulatory animal toxicity, DART, and carcinogenicity models.

Phase 2 (Pilot): Integrate human-derived multi-organ barrier chips and high-throughput genotoxicity screening platforms.

Phase 3 (Integration): Implement quantitative AI-driven adverse outcome pathways (AOP) and computational PBPK software frameworks.

Phase 4 (Standardisation): Replace 100% of high-severity regulatory safety testing and multi-disease animal modelling with qualified, human-specific NAM arrays.

Strategic Note: Building institutional expertise in high-maturity human-relevant NAMs is essential for bridging the translational gap in safety science. By training staff in the deployment of complex multi-organ toxicology chips and the 3Rs Project Licence Support Toolkit, the institution fulfills its statutory duty under *ASPA 1986*.

Final Compliance Statement

All proposed models satisfy the Section 2A statutory duty of *ASPA 1986*. By adopting these methodologies, the institution positions itself at the forefront of the global transition toward human-centric, cruelty-free medical science.

Core Specialised Cross-Cuttingting & Safety Platforms

8.1 Toxicology Models: Systemic Toxicity & Clearance

This section covers platforms for modelling systemic toxicity and safety profiling. Landmark momentum in this area includes:

- **Multi-Organ Microphysiological Systems (MPS):** Microfluidic platforms that link human liver, kidney, and barrier tissues to track long-term drug-induced injury and systemic clearance, serving as a human-relevant replacement for traditional rodent repeat-dose testing.

Artificial Intelligence (AI) and In Silico NAMs Supporting Systemic Toxicology Research

To complement advanced multi-organ systems, in silico and AI-driven methodologies play a critical role in safety and clearance assessment:

- **AlphaFold (DeepMind):** An AI system predicting protein structures, RNA, and ligand interactions to support target safety and drug clearance profiling with far fewer molecules per program.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to predict chemical behaviour, absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) endpoints with high subpopulation robustness and accuracy.

8.2 Developmental & Reproductive Toxicology (DART): Maternal-Fetal Interplay

This section covers platforms for assessing reproductive and endocrine safety. Landmark momentum in this area includes:

- **Placental Barrier-on-a-Chip Architecture:** Advanced microfluidic models that simulate the maternal-fetal interface to evaluate drug transfer kinetics.
- **Human Embryonic Stem Cell (hESC) Differentiation Assays:** Systems designed to accurately quantify chemical transport and teratogenic risks without invasive animal gestational tests.

Artificial Intelligence (AI) and In Silico NAMs Supporting DART Research

To complement advanced in vitro reproductive models, in silico and AI-driven methodologies play a critical role in predicting developmental toxicity:

- **AlphaFold (DeepMind):** An AI system predicting protein structures and ligand interactions to analyse hormone receptors and developmental pathways.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to predict endocrine disruption, teratogenicity, and reproductive safety endpoints with high accuracy.

8.3 Carcinogenicity & Genotoxicity Models: Mutagenesis & Transformation

This section covers models of tumor induction and DNA damage. Landmark momentum in this area includes:

- **3D Human Micro-Tissue Micronucleus Assays:** High-content multi-parametric screening tools that evaluate chromosomal aberrations and DNA damage.
- **In Vitro Cell Transformation Frameworks:** Testing strategies that map human-specific DNA repair mechanisms and mutagenic potential, superseding legacy two-year rodent bioassays.

Artificial Intelligence (AI) and In Silico NAMs Supporting Genotoxicity Research

To complement advanced in vitro genotoxicity models, in silico and AI-driven methodologies play a critical role in mapping mutagenic risks:

- **AlphaFold (DeepMind):** An AI system predicting protein structures and DNA-ligand interactions to analyse damage response proteins and molecular binding profiles.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to predict structural alerts for mutagenicity, carcinogenicity, and DNA reactivity with high robustness.

8.4 Aging & Cellular Senescence Models: Longevity & Degeneration

This section covers platforms for modelling aging pathways. Landmark momentum in this area includes:

- **Induced Senescent 3D Tissue Scaffolds:** Human cell-based models used to monitor the secretion profile of the Senescence-Associated Secretory Phenotype (SASP) while avoiding the excessive temporal and financial costs of long-term mouse aging colonies.

Artificial Intelligence (AI) and In Silico NAMs Supporting Aging Research

To complement advanced in vitro aging models, in silico and AI-driven methodologies play a critical role in analysing longevity pathways:

- **AlphaFold (DeepMind):** An AI system predicting protein structures and conformational changes associated with cellular aging and protein misfolding diseases.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to evaluate anti-aging compounds, biomarker correlations, and oxidative stress signatures with high accuracy.

8.5 Rare Disease Models (cross-cutting): Targeted Pathophysiology

This section covers platforms for evaluating orphan diseases across organ systems. Landmark momentum in this area includes:

- **Patient-Specific iPSC-Derived Organoids:** Specialized cellular models that isolate precise genetic mutations (such as in cystic fibrosis or rare metabolic disorders) to evaluate targeted therapeutics where traditional animal models are non-existent or genetically divergent.

Artificial Intelligence (AI) and In Silico NAMs Supporting Rare Disease Research

To complement patient-specific organoids, in silico and AI-driven methodologies play a critical role in orphan drug development:

- **AlphaFold (DeepMind):** An AI system predicting mutant protein structures and ligand interactions to fast-track precision medicine for rare genetic disorders.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to map rare disease pathways and predict patient-specific therapeutic responses with high subpopulation robustness.

8.6 Paediatric Disease Models: Juvenile Maturation Pathways

This section covers platforms for modelling child-specific disease kinetics. Landmark momentum in this area includes:

- **Juvenile Tissue Organoids:** Advanced models that mimic the physiological, metabolic, and developmental maturation profiles of infant and child organs to replace non-predictive juvenile animal testing.

Artificial Intelligence (AI) and In Silico NAMs Supporting Paediatric Research

To complement juvenile tissue platforms, in silico and AI-driven methodologies play a critical role in simulating child-specific pharmacokinetics:

- **AlphaFold (DeepMind):** An AI system predicting protein structures and developmental isoform variations unique to paediatric biological systems.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to simulate paediatric absorption, metabolism, and safety margins across developmental milestones.

8.7 3Rs Implementation & Project Licence Support Toolkit: Regulatory Translation

This section covers the institutional mechanism for protocol transition. Landmark momentum in this area includes:

- **3Rs Evidentiary Data Bundle Framework:** Structured packages providing Principal Investigators with pre-validated human-relevant data, mechanistic justifications, and cross-species comparisons to successfully satisfy Home Office/ASRU inspector replacement mandates during project licence (PPL) submission.

Artificial Intelligence (AI) and In Silico NAMs Supporting Regulatory Translation

To complement the 3Rs evidentiary framework, in silico and AI-driven methodologies play a critical role in streamlining regulatory submissions:

- **AlphaFold (DeepMind):** An AI system providing structural evidence of target engagement and molecular safety to strengthen data packages for regulatory review.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Validated predictive models used to generate standardised, transparent, and reproducible safety data that align with FDA, EMA, and MHRA guidance frameworks.

Core Specialised Platforms

These integrated enabling platforms provide the multi-scale predictive power required for regulatory validation across all toxicological and cross-cutting disease frameworks. By combining real-time multi-organ sensing with advanced computational systems, these technologies enable robust "Weight-of-Evidence" (WoE) packages that directly support the replacement of high-severity invasive animal models with human-relevant, predictive data.

FIGURE 1: THE HUMAN-RELEVANT CROSS-CUTTING & SAFETY PIPELINE: TRANSITIONING TO HUMAN MICROPHYSIOLOGICAL SYSTEMS




Figure 1: The Human-Relevant Cross-Cutting & Safety Pipeline

Description: A schematic flow diagram illustrating the transition from traditional, low-predictivity animal models (e.g., chronic repeat-dose rodent assays, animal DART testing, two-year carcinogenicity bioassays) to high-fidelity human Microphysiological Systems (MPS) and specialised toolkits. The figure contrasts "Evolutionary Divergence" (differences in xenobiotic metabolism, gestational timelines, and cellular transformation mechanisms) against the "Human-Centric Solution". This solution incorporates multi-organ toxicology chips, placental barrier models, high-throughput genotoxicity arrays, and the 3Rs Project Licence Support Toolkit to replace legacy animal testing, mitigate translational failure, and generate high-fidelity, human-relevant predictive data for regulatory approval.

Table 1: Core Specialised Platform

Focus Area	Primary Animal Model	NAM Replacement Technology	ASPA 1986 Status
8.1 Toxicology	Repeat-dose rodent testing	Multi-Organ Barrier MPS	High
8.2 DART	In vivo gestational rodent tests	Placental-Chip / hESC Assays	High
8.3 Carcinogenicity	Two-year rodent bioassays	3D Micronucleus Transformation	High
8.4 Aging	Aged mouse colonies	Induced Senescent Scaffolds	High
8.5 Rare Disease	Transgenic animal models	Patient iPSC Disease Organoids	High
8.6 Paediatric	Juvenile animal testing	Maturing Juvenile Organoids	High
8.7 PPL Support	Manual 3Rs review protocols	3Rs Evidentiary Toolkit	High

Cross-Cutting & Enabling Platforms




Figure 2: Integration of Predictive Toxicology Platforms

Description: A comparative matrix highlighting the reduction of "Translational Failure Rates" by deploying human-specific NAMs in safety testing. It visualises how toxicology-specialised chips and validation toolkits provide real-time sensing of multi-organ toxicity markers (e.g., cell death, DNA double-strand breaks, placental transport efficiency, and metabolic clearance rates), effectively replacing high-severity animal safety and chronic toxicity challenges.

Table 2: Genomic & Computational Frameworks

Platform	Key Applications	Benefits for Universities & 3Rs
Digital PBPK Mapping	Simulating human systemic drug clearance	Bypasses repeat-dose rodent trials
Adverse Outcome Algorithms	Predicting cellular transformation and toxicity	Replaces chronic in vivo animal assays
Multi-Scale Safety Map	Documenting human-relevant toxicogenomics	Regulatory WoE for Replacement

Integration Context: Roadmap Conclusion

Mapping these specialised NAMs into a unified regulatory framework is the essential prerequisite for fulfilling our ASPA 1986 statutory duty. By transitioning from isolated *in vivo* experiments to integrated, multi-organ microphysiological systems and utilizing dedicated project license toolkits, the institution establishes a robust, human-centric research pipeline that is scientifically accurate, ethically aligned, and highly predictive of human clinical outcomes.

Skills • Training, and Capacity Building

Successful adoption of high-maturity NAMs in toxicological and cross-cutting research fields requires a strategic shift in workforce development. To ensure the long-term success of the platforms outlined in this series, universities should prioritise the following initiatives:

Integrated Multi-Organ Engineering: Training programmes must bridge the gap between primary cell co-cultures, microfluidic interconnectivity, and the quantitative tracing of systemic toxicological kinetics.

Regulatory Dossier Formulation: Staff should receive formal training on translating NAM data into "Fit-for-Purpose" verification formats that directly satisfy Home Office/ASRU inspector expectations during PPL submission.

In Silico / In Vitro Integration: Developing competencies in marrying computational toxicokinetics (PBPK/QSAR) with multi-organ chip readouts to deliver robust evidence packages.

Table 3: Skills • Training & Capacity Building

Platform	Key Applications	Benefits for Universities & 3Rs
Digital PBPK Mapping	Simulating human systemic drug clearance	Bypasses repeat-dose rodent trials
Adverse Outcome Algorithms	Predicting cellular transformation and toxicity	Replaces chronic in vivo animal assays
Multi-Scale Safety Map	Documenting human-relevant toxicogenomics	Regulatory WoE for Replacement

Clinical Translation Studies

Toxicology & DART Models

Disease Modelling: Human multi-organ barrier chips and hESC-derived lineages are currently deployed to track off-target toxicities and developmental disruptors, providing a human-centric baseline that conventional animal screens misrepresent.

Translational Efficacy: These platforms evaluate specific molecular endpoints and barrier transport metrics, delivering high-fidelity safety profiles that scale efficiently into human clinical contexts.

Translational Challenges: System stabilisation and the preservation of precise cell-to-fluid volume ratios remain primary focus points for expanding multi-organ validation metrics.
Carcinogenicity & Genotoxicity Frameworks

Safety Assessment: 3D micro-tissue transformation and high-throughput micronucleus testing are increasingly integrated into early-stage testing pipelines, giving clear indication of DNA adduct formations and structural damage.

Predictive Power: By evaluating human DNA damage response paths directly, these systems mitigate the "false positive" results frequently recorded during non-human rodent bioassays.

Rare & Paediatric Disease Platforms

Targeted Interventions: Patient-derived organoids and juvenile maturation matrices are applied to map physiological responses in fragile or ultra-rare cohorts, serving as a viable clinical model where functional animal models are non-existent.

Summary of Clinical Translational Pathway: Preclinical researchers are continuously optimising these systems to establish verified, animal-free safety files. Broader regulatory qualification relies heavily on global data standardisation, automated platform scaling, and targeted policy updates from regulatory networks.

Strategic Roadmap Summary

1. Vision & Mandate

This roadmap outlines the institutional transition from traditional *in vivo* animal models to high-fidelity, human-relevant Non-Animal Methodologies (NAMs). Driven by the Section 2A statutory duty of the *Animals (Scientific Procedures) Act 1986*, this strategy prioritises the adoption of human-centric platforms to enhance the scientific validity, reproducibility, and ethical alignment of our research output.

2. Landmark Regulatory & Scientific Momentum

Toxicology Models (8.1): Utilising multi-organ microphysiological systems to replicate human systemic toxicity profiles, replacing rodent repeat-dose testing.

DART Models (8.2): Implementing human placental barrier-on-a-chip and stem cell assays to accurately monitor gestational toxicities, superseding *in vivo* animal challenge paradigms.

Carcinogenicity & Genotoxicity (8.3): Adopting 3D human micro-tissue micronucleus assays to chart mechanistic DNA damage, replacing two-year rodent bioassays.

Aging Models (8.4): Deploying induced senescent 3D tissue architectures to map longevity and degenerative phenotypes, eliminating long-term aged mouse housing.

Rare Disease Models (8.5): Utilising patient-specific iPSC-derived organoids to target precise orphan pathologies, bypassing genetically divergent transgenic animal paths.

Paediatric Disease Models (8.6): Adopting juvenile tissue organoids to mimic correct infant physiological maturation kinetics, replacing juvenile animal protocols.

3Rs & PPL Support (8.7): Deploying pre-validated evidentiary data toolkits to give principal investigators seamless replacement text for Home Office/ASRU project licensing.

3. Strategic De-Risking

Financial & Temporal Efficiency: Early-stage identification of off-target toxicities via NAMs prevents the catastrophic costs associated with late-stage clinical trial failures.

Precision Modelling: Moving away from rodent models mitigates the risk of "false positives" driven by species-specific differences in toxicology and DNA repair paths that do not occur in humans.

Data Integrity: Transitioning to human-derived data strengthens "Weight-of-Evidence" submissions, directly increasing the probability of project license (PPL) approval by the Home Office/ASRU.

4. Compliance & Institutional Commitment

Integration Context: Mapping these specialised models into a unified regulatory framework is the essential prerequisite for fulfilling our *ASPA 1986* statutory duty, ensuring all research is scientifically accurate and ethically aligned.

Final Compliance Statement: All proposed models satisfy the Section 2A statutory duty of *ASPA 1986*. By adopting these methodologies, the institution positions itself at the forefront of the global transition toward human-centric, cruelty-free medical science.